Skip to main content

Table 1 Antibiotic susceptibility profiles of K. pneumoniae. The results of antimicrobial susceptibility testing - antibiotics MIC (mg/L) and breakpoint interpretation or epidemiological cut-off value

From: Molecular characterization of carbapenem-resistant Klebsiella pneumoniae isolates with focus on antimicrobial resistance

Isolates1566D1567D2035D2036D2037D2038D2039D2040D
sourcesputumbilesputumsputumbloodsputumsputumenvironment
InfectionPulmonaryAbdominalPulmonaryPulmonaryPulmonaryPulmonaryPulmonaryN/A
ampicillin≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)
ampicillin/sulbactam≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)≥32(R)
piperacillin/tazobactam≥128(R)≥128(R)≥128(R)≥128(R)≥128(R)≥128(R)≥128(R)≥128(R)
cefazolin≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
cefotetan≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
ceftazidime≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
ceftriaxone≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
cefepime≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
aztreonam≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
imipenem≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)
amikacin≥64(R)≤4(S)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)≥64(R)
gentamicin≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)
tobramycin≥16(R)≤2(S)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)≥16(R)
ciprofloxacin≥4(R)≥4(R)≥4(R)≥4(R)≥4(R)≥4(R)≥4(R)≥4(R)
levofloxacin≥8(R)≥8(R)≥8(R)≥8(R)≥8(R)≥8(R)≥8(R)≥8(R)
macrodantin256(R)256(R)≥512(R)≥512(R)≥512(R)≥512(R)≥512(R)≥512(R)
sulfamethoxazole/trimethoprim≥320(R)≤20(S)≤20(S)≤20(S)≤20(S)≥320(R)≥320(R)≥320(R)
  1. S susceptible, I intermediate, R resistant